Literature DB >> 21849352

Granulocyte colony-stimulating factor treatment plus dipeptidylpeptidase-IV inhibition augments myocardial regeneration in mice expressing cyclin D2 in adult cardiomyocytes.

Marc-Michael Zaruba1, Wuqiang Zhu, Mark H Soonpaa, Sean Reuter, Wolfgang-Michael Franz, Loren J Field.   

Abstract

AIMS: Although pharmacological interventions that mobilize stem cells and enhance their homing to damaged tissue can limit adverse post-myocardial infarction (MI) remodelling, cardiomyocyte renewal with this approach is limited. While experimental cell cycle induction can promote cardiomyocyte renewal following MI, this process must compete with the more rapid processes of scar formation and adverse remodelling. The current study tested the hypothesis that the combination of enhanced stem cell mobilization/homing and cardiomyocyte cell cycle induction would result in increased myocardial renewal in injured hearts. METHODS AND
RESULTS: Myocardial infarction was induced by coronary artery ligation in adult MHC-cycD2 transgenic mice (which exhibit constitutive cardiomyocyte cell cycle activity) and their non-transgenic littermates. Mice were then treated with saline or with granulocyte colony-stimulating factor (G-CSF) plus the dipeptidylpeptidase-IV (DPP-IV) inhibitor Diprotin A (DipA) for 7 days. Infarct thickness and cardiomyocyte number/infarct/section were significantly improved in MHC-cycD2 mice with G-CSF plus DipA treatment when compared with MHC-cycD2 transgene expression or G-CSF plus DipA treatment alone. Echocardiographic analyses revealed that stem cell mobilization/homing and cardiomyocyte cell cycle activation had an additive effect on functional recovery.
CONCLUSION: These data strongly suggest that G-CSF plus DPP-IV inhibition, combined with cardiomyocyte cell cycle activation, leads to enhanced myocardial regeneration following MI. The data are also consistent with the notion that altering adverse post-injury remodelling renders the myocardium more permissive for cardiomyocyte repopulation.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21849352      PMCID: PMC3249220          DOI: 10.1093/eurheartj/ehr302

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  30 in total

1.  Adult cardiac stem cells are multipotent and support myocardial regeneration.

Authors:  Antonio P Beltrami; Laura Barlucchi; Daniele Torella; Mathue Baker; Federica Limana; Stefano Chimenti; Hideko Kasahara; Marcello Rota; Ezio Musso; Konrad Urbanek; Annarosa Leri; Jan Kajstura; Bernardo Nadal-Ginard; Piero Anversa
Journal:  Cell       Date:  2003-09-19       Impact factor: 41.582

2.  VEGF-induced adult neovascularization: recruitment, retention, and role of accessory cells.

Authors:  Myriam Grunewald; Inbal Avraham; Yuval Dor; Esther Bachar-Lustig; Ahuva Itin; Steffen Jung; Steffen Yung; Stephano Chimenti; Limor Landsman; Rinat Abramovitch; Eli Keshet
Journal:  Cell       Date:  2006-01-13       Impact factor: 41.582

3.  Cardiomyocyte cell cycle activation ameliorates fibrosis in the atrium.

Authors:  Hidehiro Nakajima; Hisako O Nakajima; Klaus Dembowsky; Kishore B S Pasumarthi; Loren J Field
Journal:  Circ Res       Date:  2005-11-23       Impact factor: 17.367

4.  Assessment of cardiomyocyte DNA synthesis in normal and injured adult mouse hearts.

Authors:  M H Soonpaa; L J Field
Journal:  Am J Physiol       Date:  1997-01

5.  G-CSF prevents cardiac remodeling after myocardial infarction by activating the Jak-Stat pathway in cardiomyocytes.

Authors:  Mutsuo Harada; Yingjie Qin; Hiroyuki Takano; Tohru Minamino; Yunzeng Zou; Haruhiro Toko; Masashi Ohtsuka; Katsuhisa Matsuura; Masanori Sano; Jun-ichiro Nishi; Koji Iwanaga; Hiroshi Akazawa; Takeshige Kunieda; Weidong Zhu; Hiroshi Hasegawa; Keita Kunisada; Toshio Nagai; Haruaki Nakaya; Keiko Yamauchi-Takihara; Issei Komuro
Journal:  Nat Med       Date:  2005-02-20       Impact factor: 53.440

6.  Cyclin D1 overexpression promotes cardiomyocyte DNA synthesis and multinucleation in transgenic mice.

Authors:  M H Soonpaa; G Y Koh; L Pajak; S Jing; H Wang; M T Franklin; K K Kim; L J Field
Journal:  J Clin Invest       Date:  1997-06-01       Impact factor: 14.808

7.  Targeted expression of cyclin D2 results in cardiomyocyte DNA synthesis and infarct regression in transgenic mice.

Authors:  Kishore B S Pasumarthi; Hidehiro Nakajima; Hisako O Nakajima; Mark H Soonpaa; Loren J Field
Journal:  Circ Res       Date:  2004-12-02       Impact factor: 17.367

Review 8.  Molecular mechanisms of myocardial remodeling.

Authors:  B Swynghedauw
Journal:  Physiol Rev       Date:  1999-01       Impact factor: 37.312

9.  Formation of nascent intercalated disks between grafted fetal cardiomyocytes and host myocardium.

Authors:  M H Soonpaa; G Y Koh; M G Klug; L J Field
Journal:  Science       Date:  1994-04-01       Impact factor: 47.728

10.  Haematopoietic stem cells do not transdifferentiate into cardiac myocytes in myocardial infarcts.

Authors:  Charles E Murry; Mark H Soonpaa; Hans Reinecke; Hidehiro Nakajima; Hisako O Nakajima; Michael Rubart; Kishore B S Pasumarthi; Jitka Ismail Virag; Stephen H Bartelmez; Veronica Poppa; Gillian Bradford; Joshua D Dowell; David A Williams; Loren J Field
Journal:  Nature       Date:  2004-03-21       Impact factor: 49.962

View more
  16 in total

Review 1.  Glucagon-like peptide-1 and its cardiovascular effects.

Authors:  Kyung-Sun Heo; Keigi Fujiwara; Jun-ichi Abe
Journal:  Curr Atheroscler Rep       Date:  2012-10       Impact factor: 5.113

2.  Targeted expression of cyclin D2 ameliorates late stage anthracycline cardiotoxicity.

Authors:  Wuqiang Zhu; Sean Reuter; Loren J Field
Journal:  Cardiovasc Res       Date:  2019-04-15       Impact factor: 10.787

Review 3.  Molecular and clinical roles of incretin-based drugs in patients with heart failure.

Authors:  Bassant Orabi; Rasha Kaddoura; Amr S Omar; Cornelia Carr; Abdulaziz Alkhulaifi
Journal:  Heart Fail Rev       Date:  2018-05       Impact factor: 4.214

Review 4.  Cardiovascular biology of the incretin system.

Authors:  John R Ussher; Daniel J Drucker
Journal:  Endocr Rev       Date:  2012-02-08       Impact factor: 19.871

Review 5.  Influence of Dipeptidyl Peptidase-4 (DPP4) on Mesenchymal Stem-Cell (MSC) Biology: Implications for Regenerative Medicine - Review.

Authors:  Bárbara Torrecillas-Baena; María Ángeles Gálvez-Moreno; José Manuel Quesada-Gómez; Gabriel Dorado; Antonio Casado-Díaz
Journal:  Stem Cell Rev Rep       Date:  2021-10-22       Impact factor: 5.739

6.  G-CSF displays restricted ability to promote Sca-1(+) cardiac stem cell proliferation in vitro.

Authors:  Haijian Luo; Giulio Bassi; Maddalena Tessari; Zhenyu Yang; Giuseppe Faggian
Journal:  Mol Cell Biochem       Date:  2014-08-27       Impact factor: 3.396

7.  VEGF nanoparticles repair the heart after myocardial infarction.

Authors:  Yasin Oduk; Wuqiang Zhu; Ramaswamy Kannappan; Meng Zhao; Anton V Borovjagin; Suzanne Oparil; Jianyi Jay Zhang
Journal:  Am J Physiol Heart Circ Physiol       Date:  2017-11-03       Impact factor: 4.733

8.  CCND2 Overexpression Enhances the Regenerative Potency of Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes: Remuscularization of Injured Ventricle.

Authors:  Wuqiang Zhu; Meng Zhao; Saidulu Mattapally; Sifeng Chen; Jianyi Zhang
Journal:  Circ Res       Date:  2017-10-10       Impact factor: 17.367

9.  Smooth Muscle Specific Ablation of CXCL12 in Mice Downregulates CXCR7 Associated with Defective Coronary Arteries and Cardiac Hypertrophy.

Authors:  Santhosh Kumar Ghadge; Moritz Messner; Herbert Seiringer; Thomas Maurer; Simon Staggl; Tanja Zeller; Christian Müller; Daniela Börnigen; Wolfgang J Weninger; Stefan H Geyer; Sieghart Sopper; Anne Krogsdam; Gerhard Pölzl; Axel Bauer; Marc-Michael Zaruba
Journal:  Int J Mol Sci       Date:  2021-05-31       Impact factor: 5.923

10.  Cardiomyocyte proliferation and progenitor cell recruitment underlie therapeutic regeneration after myocardial infarction in the adult mouse heart.

Authors:  Konstantinos Malliaras; Yiqiang Zhang; Jeffrey Seinfeld; Giselle Galang; Eleni Tseliou; Ke Cheng; Baiming Sun; Mohammad Aminzadeh; Eduardo Marbán
Journal:  EMBO Mol Med       Date:  2013-01-29       Impact factor: 12.137

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.